While the patient profile in this study in terms of higher levels of TG-rich lipoproteins is certainly a good idea, inclusion of steatohepatitis and diabetes may not be something that is expected to be improved by inhibiting the activity of an agent such as ANGPTL3 that would inhibit egress of lipids from the liver. This evidence concerns the gene ANGPTL3 and diabetes mellitus.